Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion

Nephrology Dialysis Transplantation

Volumn 27, Issue 2, 2012, Pages 548-556

  Pletinck, Anneleen ^a   Van Landschoot, Maria ^a   Steppan, Sonja ^b   Laukens, Debby ^a   Passlick Deetjen, Jutta ^c   Vanholder, Raymond ^a   Van Biesen, Wim ^a  

^a GHENT UNIVERSITY   (Belgium)

^b FRESENIUS MEDICAL CARE   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

angiogenesis; fibrosis; peritoneal dialysis; peritoneal membrane; sulodexide

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CREATININE; CYTOKERATIN; GLUCOSE; SODIUM; SULODEXIDE; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIALYSATE; DIFFUSION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GLUCOSE TRANSPORT; IMMUNOHISTOCHEMISTRY; MESOTHELIUM; NONHUMAN; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RAT; SAMPLING; TISSUE BLOOD FLOW; ULTRAFILTRATION;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BIOPSY, NEEDLE; DIALYSIS SOLUTIONS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSAMINOGLYCANS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PATHOLOGIC; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEUM; RANDOM ALLOCATION; RATS; RATS, WISTAR; REFERENCE VALUES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856932717     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr370     Document Type: Article

References (59)

1. Lameire N, Van Biesen W, Vanholder R. The role of peritoneal dialysis as first modality in an integrative approach to patients with end-stage renal disease. Perit Dial Int 2000; 20 (Suppl 2): S134-S141
2. Van Biesen W, Vanholder R, Lameire N. The role of peritoneal dialysis as the first-line renal replacement modality. Perit Dial Int 2000; 20: 375-383
3. De Vriese AS, Mortier S, Lameire NH. What happens to the peritoneal membrane in long-term peritoneal dialysis? Perit Dial Int 2001; 21 (Suppl 3): S9-S18
4. Mateijsen MA, van der Wal AC, Hendriks PM et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-525
5. Williams JD, Craig KJ, von RC et al. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl 2003; 88: S43-S49
6. Stoenoiu MS, De Vriese AS, Brouet A et al. Experimental diabetes induces functional and structural changes in the peritoneum. Kidney Int 2002; 62: 668-678
7. Ha H, Lee HB. Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int 2000; 20 (Suppl 2): S15-S18
8. Sitter T, Sauter M. Impact of glucose in peritoneal dialysis: saint or sinner? Perit Dial Int 2005; 25: 415-425
9. Tyrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995; 16: 198-204
10. De Vriese AS, Mortier S, Cornelissen M et al. The effects of heparin administration in an animal model of chronic peritoneal dialysate exposure. Perit Dial Int 2002; 22: 566-572
11. De Vriese AS, Mortier S, Lameire NH. Non anticoagulant effects of heparin: implications for animal models of peritoneal dialysis. Perit Dial Int 2001; 21 (Suppl 3): S354-S356
12. Margetts P. Heparin and the peritoneal membrane. Perit Dial Int 2009; 29: 16-19
13. Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov Technol 2009; 6: 281-289
14. De Vriese AS, Mortier S, Lameire NH. Glucotoxicity of the peritoneal membrane: the case for VEGF. Nephrol Dial Transplant 2001; 16: 2299-2302
15. Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol 2010; 21: 1077-1085
16. Lai KN, Tang SC, Leung JC. Mediators of inflammation and fibrosis. Perit Dial Int 2007; 27 (Suppl 2): S65-S71
17. Farooq V, Hegarty J, Chandrasekar T et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004; 43: 531-537
18. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev 1998; 18: 1-20
19. Lauver DA, Lucchesi BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev 2006; 24: 214-226
20. Weiss R, Niecestro R, Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs 2007; 67: 2681-2696
21. Dedov I, Shestakova M, Vorontzov A et al. A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 1997; 12: 2295-2300
22. Gambaro G, Cavazzana AO, Luzi P et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992; 42: 285-291
23. Gambaro G, Kinalska I, Oksa A et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13: 1615-1625
24. Bazzato G, Fracasso A, Gambaro G et al. Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet 1995; 346: 740-741
25. Fracasso A, Baggio B, Ossi E et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. AmJ Kidney Dis 1999; 33: 105-110
26. Cristofori M, Mastacchi R, Barbanti M et al. Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part I: pharmacokinetics in rats. Arzneimittelforschung 1985; 35: 1513-1516
27. Coccheri S, Scondotto G, Agnelli G et al. Sulodexide in the treatment of intermittent claudication. Results of a randomized, doubleblind, multicentre, placebo-controlled study. Eur Heart J 2002; 23: 1057-1065
28. Rossini M, Naito T, Yang H et al. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant 2010; 25: 1803-1810
29. Fracasso A, Baggio B, Masiero M et al. Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients. Perit Dial Int 2003; 23: 595-599
30. Zareie M, Keuning ED, ter Wee PM et al. Improvement of a chronic rat model for peritoneal dialysis by using heparin-coated catheters. Adv Perit Dial 2004; 20: 150-154
31. Mortier S, De Vriese AS, Leyssens A et al. Antibiotic administration in an animal model of chronic peritoneal dialysate exposure. Perit Dial Int 2003; 23: 331-338
32. Lambers Heerspink HJ, Greene T, Lewis JB et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 2008; 23: 1946-1954
33. CeolM, Gambaro G, Sauer U et al. Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol 2000; 11: 2324-2336
34. Zweers MM, de Waart DR, Smit W et al. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J LabClinMed 1999; 134: 124-132
35. Suzuki K, Khanna R, Nolph KD et al. Expected white blood cell counts and differentials in a rat model of peritoneal dialysis. Perit Dial Int 1995; 15: 142-146
36. Pletinck A, Consoli C, Van Landschoot M et al. Salt intake induces epithelial-to-mesenchymal transition of the peritoneal membrane in rats. Nephrol Dial Transplant 2010; 25: 1688-1696
37. Breborowicz A, Wieczorowska K, Martis L et al. Glycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron 1994; 67: 346-350
38. Mortier S, Faict D, Schalkwijk CG et al. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66: 1257-1265
39. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479
40. Zweers MM, Splint LJ, Krediet RT et al. Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 2001; 16: 651-654
41. Diaz-Buxo JA, Gotloib L. Agents that modulate peritoneal membrane structure and function. Perit Dial Int 2007; 27: 16-30
42. Vrtovsnik F, Coester AM, Lopes-Barreto D et al. Induction of chronic kidney failure in a long-term peritoneal exposure model in the rat: effects on functional and structural peritoneal alterations. Perit Dial Int 2010; 30: 558-569
43. Niers TM, Klerk CP, DiNisioMet al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007; 61: 195-207
44. Soker S, Goldstaub D, Svahn CM et al. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors. Biochem Biophys Res Commun 1994; 203: 1339-1347
45. Pyda M, Korybalska K, Ksiazek K et al. Effect of heparin on blood vascular endothelial growth factor levels in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2006; 98: 902-905
46. Ruggeri A, Guizzardi S, Franchi M et al. Pharmacokinetics and distribution of a fluoresceinated glycosaminoglycan, sulodexide, in rats. Part II: organ distribution in rats. Arzneimittelforschung 1985; 35: 1517-1519
47. Breborowicz A, Pyda M, Moberly J et al. Effect of hyaluronansupplemented dialysate on in vitro function of human peritoneal mesothelial cells. Am J Nephrol 2004; 24: 316-321
48. Mizuiri S, Miyata S, Sakai K et al. Effect of intraperitoneal administration of heparin on advanced glycation end-products in CAPD. Perit Dial Int 1999; 19: 361-365
49. Pawlaczyk K, Kuzlan-Pawlaczyk M, Anderstam B et al. Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis. Nephrol Dial Transplant 2001; 16: 669-671
50. Ponce SP, Barata JD, Santos JR. Interference of heparin with peritoneal solute transport. Nephron 1985; 39: 47-49
51. Schilte MN, Loureiro J, Keuning ED et al. Long-term intervention with heparins in a rat model of peritoneal dialysis. Perit Dial Int 2009; 29: 26-35
52. Karon J, Polubinska A, Antoniewicz AA et al. Anti-inflammatory effect of sulodexide during acute peritonitis in rats. Blood Purif 2007; 25: 510-514
53. Sjoland JA, Smith PR, Jespersen J et al. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 2004; 19: 1264-1268
54. Breborowicz A, Polubinska A, Moberly J et al. Hyaluronan modifies inflammatory response and peritoneal permeability during peritonitis in rats. Am J Kidney Dis 2001; 37: 594-600
55. Wang T, Cheng HH, Heimburger O et al. Hyaluronan prevents the decreased net ultrafiltration caused by increased peritoneal dialysate fill volume. Kidney Int 1998; 53: 496-502
56. Flessner MF, Credit K, Richardson K et al. Peritoneal inflammation after twenty-week exposure to dialysis solution: effect of solution versus catheter-foreign body reaction. Perit Dial Int 2010; 30: 284-293
57. Ciszewicz M, Polubinska A, Antoniewicz A et al. Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity. Transl Res 2009; 153: 118-123
58. Weigert C, Brodbeck K, Haring HU et al. Low-molecular-weight heparin prevents high glucose-and phorbol ester-induced TGF-beta 1 gene activation. Kidney Int 2001; 60: 935-943
59. Combet S, Ferrier ML, Van LM et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001; 12: 2146-57